ASM International Deep Value Investment Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  Conclusion first: ASM's ceiling is an existing pie on a genuinely long runway. It is expanding that pie, not creating a new market; the runway is long but not especially wide, and the FY30 growth rate the company itself gives has already slowed versus history. That fits the overall view of "good business, bad price, rating Watch."

  Framing the question correctly matters. The issue is not "how large are semiconductor equipment or ALD as a field," but "how high is the ceiling ASM can actually address, and what kind of ceiling is it." The answer is that ASM is increasing its share and volume inside an existing structurally growing pie, namely advanced deposition, especially single-wafer ALD and Epitaxy, rather than opening a market that did not exist before. This runway is real, but ASM's addressable volume is only "a small slice" of overall WFE, and growth is fully parasitic on the capex cycle of leading-edge wafer fabs. That is the root cause of its "high ceiling but cyclically colored growth."

  1. ASM's real ceiling is the deposition submarket it serves, just over US$10 billion, not the US$100 billion-plus overall WFE market. Global wafer fabrication equipment (WFE) in 2025-2026 is roughly in the US$110 billion-US$135 billion range (SEMI expects semiconductor equipment sales to reach a record US$156 billion in 2027; multiple institutions put 2026 WFE at about US$113.5 billion-US$135.2 billion). But ASM does not sell "all WFE." It sells specific categories within deposition. Based on ASM's official 2025 Investor Day framing, the two markets it truly serves are: single-wafer ALD, US$3.0 billion (2024) -> US$5.1 billion-US$6.1 billion (2030), and Epitaxy, US$1.5 billion (2024) -> US$2.5 billion-US$3.2 billion (2030). Together, ASM's core serviceable market was about US$4.5 billion in 2024 and should be about US$7.6 billion-US$9.3 billion by 2030. That is the size of its "pie," a single-digit percentage slice of overall WFE. The report makes this clear: ASM operates in "not all WFE, but the deposition subsegment within it," making it "an excellent niche champion in a good industry, not a full-flow ruler."

  2. Category judgment: this is "expanding an existing pie," not "creating a new market." ALD, Epi, vertical furnaces, and PECVD are all long-established process steps in advanced manufacturing. ASM's 2025 revenue of €3.17 billion all came from selling more of these mature equipment categories into growing wafer fabs, with services and spares expanding from the installed base. Its growth engine is "rising unit intensity + expanding own share," not demand created from thin air: GAA/2nm/1.4nm increase the number of ALD/Epi steps per chip (higher ALD intensity), and DRAM's transition from 6F² to 4F² lifts ALD+Epi usage. These forces make the same pie thicker and larger. The company's own SAM additions are also existing-market expansion from node migration, not new markets: first-generation GAA adds US$400 million of SAM2 for ASM versus 3nm FinFET; the transition to 1.4nm adds another US$450 million-US$500 million; the DRAM 4F² migration adds another US$400 million-US$450 million. The Baillie Gifford-style ideal of "creating a market that did not previously exist," such as taking a brand-new category from zero to mainstream, does not apply here. ASM is the leader increasing share and usage inside an existing deposition market.

  3. Its share is already high (>55%), so the room to lift the ceiling by taking share is relatively limited. More of the growth is "rising with the market." ASM's single-wafer ALD share has already exceeded 55% (Q1 2026 again reiterated leading >55% ALD market share, consistent with the report body and digest). This is already an absolute-leadership, mature-leadership position, which means it is hard to lift the ceiling dramatically by taking additional share. Future additions mainly come from expansion of the ALD/Epi market itself (~9-13% CAGR) plus share gains in Epi, where its share is not yet capped and still expanding. In other words, ASM's ceiling is more of a "market-growth-determined ceiling" than a low-penetration ceiling where share gains can create geometric expansion. That differs from the Baillie-style profile of "very low penetration, fivefold growth over a decade."

  4. The key honest point: ASM's own FY30 target implies a "growth slowdown" versus history. From 2021 to 2025, ASM revenue rose from €1.73 billion to €3.17 billion, a four-year CAGR of about 16% (report financial table). The official FY30 target is revenue >€5.7 billion (€5.7bn), corresponding to 2024-2030 CAGR of "at least 12%," clearly outperforming the WFE market's roughly 6% CAGR. From €3.17 billion in 2025 to >€5.7 billion in 2030, the coming five years imply only about 12% CAGR, below the past four years' 16%. This is the most honest description of the ceiling's growth character: the long runway remains, and ASM can keep beating the market, but the slope is flattening, well short of the Baillie hard threshold of "fivefold in the next ten years" (about 17.5% annualized). FCF target >€1.0 billion and operating margin 28%-32% (2030 >30%) show high quality, but not enough growth magnitude for a fivefold narrative.

  5. Fragility of the ceiling: it is parasitic on customer capex and highly concentrated. Even if that ceiling is real, realizing it is not under ASM's own control. It depends on the expansion timing of a small number of large customers and the AI capex cycle. That is the essence of a strong-cycle business. The report states that the top five customers account for about 53% of revenue, the top ten about 72%, and two customers each contribute >10%; China equipment revenue still accounts for 30%+ and is exposed to export controls. If demand is delayed, whether from customers postponing GAA/advanced packaging adoption, AI capex cooling, or tighter China restrictions, ASM can quickly move from the valuation framework of a "high-growth equipment company" back to that of a "cyclical equipment company." So this is not a consumer-style, self-driven, smooth ceiling that the company can actively penetrate. It is a niche ceiling of limited addressable volume that moves up and down with other companies' capex cycles.

  Summary (Question 1 scoring tendency: medium). ASM's market ceiling is high enough, the runway is long enough, and it can keep outperforming the broader market. That is the foundation of its quality as a business and deserves credit. But by the standard of this Baillie question, it is expanding an existing pie, not creating a new market; its own addressable market is only a small part of overall WFE; an existing >55% share limits the elasticity of "lifting the ceiling through share gains"; official FY30 growth (~12%) is slower than history (~16%) and slowing; and growth is highly dependent on customer capex cycles and concentrated customers. Overall, this dimension lands at medium: real quality and a credible long runway, but not new-market creation, and not a growth rate that supports the extreme "fivefold in ten years" imagination. That is fully consistent with the report's "good business, bad price, rating Watch" conclusion and should not be inflated to fit a growth-stock narrative.

  Jun 5, 2026
• QCan its revenue at least double over the next five years? Is growth mainly driven by volume, price, or new businesses?5/10

  A

  Conclusion first

  Revenue can probably double over the next five years, but only barely, and the growth curve is already capped by official guidance. This is solid but not spectacular growth. Moving from €3.17bn to about €6.34bn requires a roughly 14.9% five-year compound growth rate. The company's own official FY30 target is revenue >€5.7bn, corresponding to "at least 12% CAGR (2024-2030)". The official guidance itself is below the five-year doubling line and leaves no cushion. This is exactly why ASM does not fit the Baillie archetype of a great growth stock that can rise fivefold over the next decade: doubling requires outperformance versus guidance, not simply executing guidance. Growth is driven mainly by volume, with price/mix as a secondary factor and new businesses as long-tail options. The structural direction is real and clear, but the ceiling is bounded by the semiconductor WFE capex cycle and roughly 12-13% TAM growth in the relevant submarkets. The conclusion fits "good business, bad price, Watch": the business's growth quality is above average, but not extreme and not cheap.

  Can doubling be achieved: the math

  • Baseline: The report records 2021 -> 2025 revenue of €1.73bn -> €3.17bn, about 16% CAGR over four years. If that historical rate were extrapolated linearly, five-year doubling would be achievable; but the historical 16% included the cyclical upturn benefit of 2021-2022, so it should not be copied into the forecast.
  • Official guidance: FY30 >€5.7bn. Starting from 2025 revenue of €3.17bn, reaching €5.7bn over 5 years implies about 12.5% CAGR; using the company's 2024 base (€2.93bn), it matches "at least 12%." Either way, the official midpoint puts five-year revenue around €5.7-5.8bn, about €0.6bn short of the €6.34bn doubling line.
  • Judgment: Doubling requires sustained annualized growth about 2.5-3 percentage points above the company's own guidance. Given that management tends to put adverse information on the table first (the report already judges that it "will put adverse information on the table"), >€5.7bn looks more like a conservative anchor than a ceiling. I judge the probability of actual doubling as neutral-to-high, about 60%, but this is "reachable on tiptoe," not the Baillie-style "easy multiple-fold" case.

  Growth-source breakdown: volume > price > new businesses

  The first driver is volume, and it is structural volume growth rather than simple cyclical replenishment. The key evidence is the submarket TAM expansion the company gave at its 2025 Investor Day: the single-wafer ALD market grows from $3.0bn to $5.1-6.1bn from 2024 to 2030 (9-13% CAGR), and Epi from $1.5bn to $2.5-3.2bn (9-13% CAGR). Volume growth comes from two layers: (1) wafer-fab equipment demand from AI/advanced logic capacity expansion; (2) rising unit intensity, because more advanced nodes require more ALD/Epi deposition steps per wafer. The company quantified the specific additions as: GAA generation + about $400m serviceable market, 1.4nm generation + $450-500m, 4F² DRAM transition + $400-450m. The report body also confirms this direction: the company says ALD and Epi serviceable markets will continue to expand in GAA entering volume production and later 1.4nm/1.0nm. Assuming ASM maintains >55% single-wafer ALD share, the TAM growth of 9-13% is essentially its volume-growth base.

  The second driver is price/product mix, positive but limited in magnitude. This is not consumer-brand pricing power. It is process-value pricing described in the report: when customers are fighting for yield and throughput at 2nm/HBM/advanced packaging, better-performing tools are less price sensitive. The evidence is steadily rising gross margin: the report records 2023 -> 2025 gross margin of 49.3% -> 50.5% -> 51.8%, and even in 2025 Q4, when revenue fell year over year, gross margin held at 49.8%. But a gross-margin lift of around 1 percentage point per year makes only a small direct contribution to revenue doubling. Price mainly improves profit quality; it is not the primary revenue-doubling engine.

  The third driver is new businesses/share expansion, a long-tail option that is unlikely to become the main force within five years. This includes: (1) Epi share gains (unlike ALD, which is defending a strong position, Epi is an active share-taking area); (2) services and spares, where the report says 2025 Spares & Services grew +18% year over year at constant currency, with a target for >50% to come from outcome-based services by 2030. This upgrades project-style revenue into recurring sticky revenue, but it remains a smaller share of total revenue; (3) M&A into new adjacent tracks, with the report recording the 2022 acquisition of LPE to enter SiC Epi and the 2025 acquisition of Axus to bring CMP into More-than-Moore/3D integration. The direction stays around adjacent interface engineering and deposition chemistry, but these moves have not yet gone through a full cycle and their real value creation remains to be verified. These are year 6-10 growth options, helpful but not decisive for "five-year doubling."

  Starting-point correction: the report's "weak start" framework is partly outdated

  The report, drafted on 2026-06-04, describes the growth starting point as a cyclical trough: weak 2025 power/analog/wafer, 2025 Q4 revenue down year over year, and 2026 Q1 free cash flow turning negative at €48m. But by the time this question was drafted, the latest quarterly report had materially improved that picture: ASM 2026 Q1 revenue was €863m, at the high end of guidance, up +16% year over year at constant currency, with gross margin of 53.3% and a record operating margin of 33.1%, driven by strong logic/foundry, AI infrastructure expansion, and a China-demand recovery; Q2 2026 guidance is revenue of €980m ±5% at constant currency, H2 is expected to be stronger than H1, advanced logic/foundry is the main driver, and 1.4nm pilot-line investment is expected to begin in H2. Sell-side consensus also moved up: after Q1, 2026 full-year revenue consensus was raised from about €3.69bn to about €3.94bn, and 2027 was raised to about $4.40bn. In other words, the cycle has turned up from the 2025 trough, and growth in the first two years has been pulled forward. That helps the five-year-doubling question, but it also means 2028-2030 growth may need to decelerate meaningfully to land near the official €5.7bn center (after roughly +24% in 2026, the remaining years imply high-single-digit to low-double-digit growth). Growth is not a smooth doubling path; it is front-loaded.

  Growth quality and honest calibration

  • Real quality, but with cyclical beta: Volume growth comes from structural node upgrades and unit intensity, not just one-off customer capacity additions. That is better than an ordinary cyclical equipment vendor; the report also shows resilience, with ASM still holding a 26.6% operating margin in a soft 2023 market. But it remains a strongly cyclical business. The report states that if customers delay adoption, AI investment cools, or advanced nodes slow, it can quickly revert from a "high-growth equipment company" to a "cyclical equipment company." The 2025 Q4 year-over-year decline was a preview.
  • Concentration amplifies volatility: Growth is highly dependent on the expansion plans of a small number of giants. The report says the top five customers accounted for about 53% of 2025 revenue, the top ten about 72%, and two customers each exceeded 10%, while China equipment revenue still accounted for 30%+ and is exposed to export-control disruption. These two factors make the path to doubling uneven and create tail risk from regulation or a single large customer's technology-roadmap change.
  • Honest Baillie-style conclusion: Looking at upside firepower in years 3-10, ASM's growth is qualified but not great. It has a long-runway story of AI x advanced nodes x ALD share, but the slope is capped by roughly 12-13% submarket TAM growth and the company's own guidance. Doubling requires beating guidance rather than comfortably executing guidance. Together with a €888 share price and about 44.5x PE, this forms "good business, bad price": the market has fully priced solid but not extreme five-year growth. On Question 2, the growth-momentum dimension, ASM is real above-average growth, not the rare Baillie-type asset with huge upside asymmetry.

  Jun 5, 2026
• QAfter five years, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion first: ASM's "second curve" is not a brand-new curve that has yet to appear. It is a set of already existing, mostly operating "track extensions" that push the existing deposition-equipment cycle toward more complex nodes and adjacent processes, rather than a separate new engine that can independently drive nonlinear growth. By the Baillie standard, the candidates that could take over after five years do exist today and have transmission paths. The two strongest paths, node evolution increasing ALD/Epi unit intensity and Epi share gains, are already operating and have been validated by orders. But the two with the strongest true "second curve" flavor, SiC Epi (LPE) and CMP (Axus), are respectively in a cyclical trough and newly consolidated at a tiny scale. Overall, these engines can probably extend high growth for several more years and lift the 2030 SAM ceiling, but they are unlikely to support the nonlinear "fivefold in ten years" story that requires a new growth pole. That matches the report's "good business, bad price, Watch" framing: the issue is not whether growth is real, but that today's €888 price has already prepaid much of the optimistic execution for these second curves.

  Candidate engines, one by one, judged on whether they are operating today and whether they can take over:

  1. Node evolution lifting ALD/Epi unit intensity: the hardest evidence, already running, and the true core successor. This is not an option; it is the self-extension mechanism of ASM's cash cow. As process technology moves toward GAA, 4F², and HBM, each wafer needs more high-aspect-ratio and conformal deposition steps, lifting ALD/Epi "unit intensity." At its 2025 Investor Day, ASM gave a quantified transmission path: versus 3nm FinFET, first-generation GAA increases ASM's serviceable available market (SAM) by about US$400m, with share gains in both ALD and Epi; the move to 1.4nm adds another US$450-500m; and DRAM's transition from 6F² to 4F², together with CMOS peri moving to FinFET, adds US$400-450m. These additions are already entering volume production or locked into tool-of-record positions, so transmission certainty is highest. The honest caveat: it is driven by unit-value increase x customer capex cycle. It still deepens and reprices the "deposition equipment business," and is not a new curve that can grow independently of wafer-fab capex. It can make ASM grow faster and enlarge SAM in good years, but it does not change the underlying identity of a cyclical equipment company. If AI/advanced logic capex cools, this curve will fall at the same time, not hedge the downturn.

  2. Epi share expansion: genuinely operating, directionally correct, and the second-strongest successor. ASM confirmed at its Investor Day that it had "achieved its strategic target for Epi share gains," and points to a 2030 Epi market of US$2.5-3.2bn. Epi shares front-end interface-engineering capabilities with ALD, and usage rises naturally in GAA channels, source/drain epitaxy, and other node steps. It exists today and is already gaining share, with a clear transmission path. But it still belongs inside ASM's core circle of competence; it is a share-expansion path, not a true "second business." It widens the main curve more than it replaces it.

  3. Outcome-based services: already present, growing strongly, and the candidate with the best "sticky curve" characteristics, but still small in absolute size. This is the candidate that best fits the Baillie taste for high-quality compounding: converting project-style spares and maintenance into recurring revenue settled by yield, output, or availability. The evidence is real: 2025 Spares & Services grew 18% at constant currency, and the company explicitly attributed this in its Q4/full-year results to the "rapid expansion of outcome-based services," while targeting >50% of that line from higher-quality revenue by 2030. It is operating and accelerating today, and it should snowball with the installed base while being more cycle-resistant than equipment sales. But discipline is needed: services remain a minority of total revenue, equipment remains the overwhelming bulk, and 18% growth is being applied to a smaller base. Within five years, this can materially improve revenue quality and stability, but it is unlikely to carry group-level nonlinear growth on its own. It is a shock absorber for the main curve, not a new engine.

  4. SiC Epi from LPE: a real "second-curve candidate," but currently a headwind rather than a tailwind. The 2022 acquisition of LPE moved ASM into SiC epitaxy equipment. Strategically, this is an independent growth pole tied to EVs/power electronics rather than advanced logic, and at the time the market expected SiC Epi equipment to grow at more than 25% CAGR from 2021-2025. The problem is that current reality has diverged from the narrative: in its 2025 results, ASM clearly said the power/analog/wafer segment declined further in 2025 (SiC/power sits in that segment), and expected only a "moderate recovery from a relatively low base" in 2026. This second curve does exist and is an adjacency rather than a foreign expansion, but it is currently in the EV/power-semiconductor destocking and capacity-digestion cycle, so it has not taken over in the short term and is instead a drag. Whether it can truly scale after five years depends on when the power-semiconductor cycle bottoms and recovers. It is a real option with highly uncertain timing, not landed growth that should be capitalized into valuation today.

  5. CMP from Axus for advanced packaging/3D integration: the newest and most attractive direction, but today it is almost only a "newly purchased option" at tiny scale. In 2025-12, ASM acquired Axus Technology, an Arizona CMP/polishing/wafer-thinning equipment company, for €81m + earn-out, bringing chemical mechanical polishing capability into More-than-Moore, 3D integration, and advanced packaging. Strategically it makes sense: CMP complements ASM's interface engineering and chemistry capabilities, and 3D stacking is a long runway of rising structural complexity. But by the Baillie standard of honesty, an €81m consideration is almost negligible versus a €44bn market value. The acquisition has only just closed and has not gone through a full integration and scale-up cycle. Today, as a "second curve that already exists," it is basically an early adjacent option. Becoming a real successor engine will require years of evidence that it can grow from a small acquisition into a meaningful business line. The report's attitude toward LPE/Axus, "positive so far but still needing verification," especially applies here.

  Returning to the Baillie question, "what takes over after five years, and does the second curve exist today?" the honest verdict is:

  • Existence: passes. All five candidates exist today and have clear technology transmission paths. None is an invented story. ASM's adjacent expansion (Epi share, SiC, CMP) and business-model upgrade (outcome-based services) are real, coherent, and built around its core circle of competence.
  • Nonlinear successor strength: qualified. The items that are currently operating and contributing growth, namely node-driven ALD/Epi unit intensity, Epi share gains, and more sticky services, are essentially extensions and deepening of the main curve. They can extend ASM's high growth, high share, and high SAM for several years and improve revenue quality, but the growth logic remains bound to wafer-fab capex cycles and does not provide a hedge independent of semiconductor capex. The two with the strongest "independent second curve" flavor, SiC Epi and CMP, are respectively in a cyclical trough and newly consolidated at immaterial scale. They are adjacent options, not landed growth poles.
  • Implication for the growth-investing framework: By the Baillie "fivefold in ten years" ruler, ASM's second curves are enough to support a credible high-quality growth story that can continue for several more years, but not enough to create the nonlinear leap that requires a new growth pole. It looks more like "installing a more efficient version of the same main engine" than "adding a second engine." That is consistent with the report's "good business, bad price, Watch" conclusion: the issue was never whether these second curves are real; they mostly are. The issue is that a €888 price and roughly 44.5x PE have already priced in optimistic successor execution, especially a SiC recovery and CMP scaling, before they are fully proven. On the second-curve dimension, my judgment is medium-to-strong but not inflated: the engines are present, the direction is right, and the two hardest ones are running, but on the highest standard of "successor curve that supports nonlinear growth", the evidence is not yet sufficient. It still needs time for the cycle and acquisition integration to prove out.

  Jun 5, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion first: ASM's moat is narrow but deep. It is not a full-category equipment ruler, but the global champion in the single-wafer ALD (atomic layer deposition) niche, with share >55%. Its strength comes from very high switching costs created by tool-of-record lock-in, years of process know-how/IP, co-development with leading wafer fabs, and a culture of sustained heavy R&D. Over the next three to five years, I judge this moat as stable with a tendency to widen, but absolutely not unassailable: advanced logic GAA, DRAM 4F², and advanced packaging will expand demand for ALD/Epi at more complex nodes rather than letting ASM live off mature nodes; at the same time, AMAT, Lam, and Tokyo Electron have deep capital and are applying pressure through platformized integration, Chinese equipment makers are accelerating substitution at mature nodes, and technology paths themselves will evolve. The moat is strong, but its narrowness keeps me from inflating the overall growth case. That is fully consistent with the report's "good business, bad price, Watch" stance.

  1. The real sources of core competitive advantage

  ASM's moat does not come from one source. Several forces overlap, and they can be checked against the report's moat table:

  • Switching costs (very strong), the hardest pillar. Before equipment enters advanced-node volume production, it needs long-cycle qualification, co-development with customers, and accumulation as the "tool-of-record." Once a specific ALD tool is selected as the production baseline for a process step, it is extremely difficult for the customer to switch during the remaining lifecycle of that node. Changing tools means requalification, retuning yield, and taking production-line risk. The report calls this "very strong," and I agree. This is the underlying reason ASM could hold 49.8% gross margin in 2025Q4 despite a year-over-year revenue decline and lift gross margin from 49.3% in 2023 to 51.8% in 2025. When customers are fighting for capacity and yield in 2nm, HBM, and advanced packaging, they are not very price sensitive toward equipment that can deliver even slightly better performance, yield, or throughput.

  • Process know-how and patents/IP (very strong). ALD is chemical engineering at atomic-layer precision. The difficulty lies in interface engineering, precursor chemistry, and conformality, not something capital can simply buy. CEO Hichem M'Saad has a deep background in materials and electronic materials science, a large body of technical papers and patents, and came up through thermal processing, global products, and CTO roles rather than arriving as a finance executive. For a technology-led equipment company, that background is itself part of the moat. ASM also keeps reinforcing the moat with IP, such as its recent €38 million purchase of a spatial ALD patent portfolio from Fraunhofer.

  • Scale advantage (moderately strong, but bounded). Within the ALD niche, ASM's high share lets it spread large R&D and supply-chain fixed costs across enough shipments, creating a positive loop. But honestly, its overall scale, breadth of product coverage, and global service-network density are still smaller than AMAT, Tokyo Electron, and Lam, the full-category leaders. That is the cost of being "narrow": ASM is a niche champion, not a full-process ruler.

  • Brand/culture/data (a technical brand, not a consumer brand). ASM's "brand" exists in the minds of customer process teams. It is engineering reputation inside a technical community. This is reinforced by the service and process database accumulated from the installed base and an operating culture backed by sustained high R&D (2025 Gross R&D €512 million, net R&D €409 million). These are positives, but they are not network effects. This is not a platform business; treating it as a data-network-effect business would overstate the moat.

  One framing point needs to be kept honest: the report's customer concentration figure, "the top five customers accounted for about 53% and the top ten for about 72% in 2025," and the separate figure I cite here that the four equipment suppliers AMAT/ASM/TEL/Lam together account for about 72% of industry revenue share, are two different dimensions of "72%." They should not be mixed: the first is ASM's customer-concentration risk; the second is supply-side industry concentration.

  2. Why I judge the moat as tending to widen over three to five years

  The widening logic is simple: ASM's existing share is not merely living off mature nodes. It advances with leading-edge process upgrades. The more advanced the node, the more ALD/Epi steps each wafer requires and the larger ASM's serviceable market becomes:

  • Advanced logic GAA: In the transition from 3nm FinFET to first-generation GAA (gate-all-around), ASM's serviceable available market (SAM) increases by about US$400 million, with share gains in both ALD and Epi. The continued move to 1.4nm GAA is expected to add another US$450 million-US$500 million of SAM for ASM, mainly in front-end (FEOL) applications where ASM leads. This is direct evidence that higher complexity benefits it.
  • DRAM 4F²: The transition from 6F² to 4F² requires more high-aspect-ratio precision deposition. The company expects a significant increase in the ALD+Epi serviceable market, consistent with the industry's direction.
  • Advanced packaging: More complex 3D structures also create incremental demand for ALD/Epi.

  In market-size terms, the single-wafer ALD market is expected to grow from about US$3.0 billion in 2024 to US$5.1-6.1 billion in 2030 (9%-13% CAGR), faster than the overall wafer-fab equipment market (about 6% CAGR). ASM itself targets maintaining >55% single-wafer ALD share in 2030 while continuing to gain share in Epi, supporting a FY30 revenue target of >€5.7 billion. To replicate ASM's position, competitors need not just money, but years of process accumulation, leading-customer qualification, and 5-10-year product-iteration cycles. That time barrier is the foundation for the "tending to widen" judgment.

  3. Narrowing risks that should not be ignored, and why this is "strong but not unassailable"

  I deliberately do not describe it as unassailable, because the following pressures are real:

  • Platformized squeeze from full-category leaders. AMAT packages deposition tools into its Integrated Materials Solution platform, letting customers skip complex integration steps; AMAT's 2024 acquisition of Picosun strengthened low-temperature ALD and pressures the dedicated ALD niche, potentially affecting ASM's ALD share. Lam uses PEALD + etch integration to lock in processes; Tokyo Electron launched the Tactras ALE-ALD cluster platform, integrating etch and deposition and improving throughput by 18% for nanosheet logic nodes. These "deposition + etch integrated cluster" strategies are exactly the flanking pressure on ASM's narrow-and-deep position. If customers prefer integrated procurement, ASM's single-process advantage may be diluted by platform integration.
  • Chinese equipment makers accelerating substitution at mature nodes. This is the other side of the report's China/regulatory risk. Mature nodes are where domestic substitution breaks through first. Advanced-node ALD is unlikely to be breached quickly, but marginal share-erosion pressure exists over the long term.
  • Technology paths can change. Deposition processes themselves evolve. Today's tool-of-record is not automatically the next node's tool-of-record. ASM must keep "renewing" its moat through sustained high R&D, which is why the relationship between capitalized development costs and net R&D deserves long-term monitoring.

  4. Implication for the investment conclusion, consistent with "Watch"

  Putting the three layers together: on the moat dimension, I rate ASM as "very strong." This is the most solid asset of ASM as an excellent niche champion in a good industry, and the view that it tends to widen over three to five years is supported by hard evidence from advanced-node SAM expansion. But "narrow" is also its ceiling characteristic: its integrated platform capability and installed-base scale are weaker than full-category leaders, and it faces flanking competition from integrated clusters. A strong moat therefore cannot prove that overall growth can be extrapolated without limit. The FY30 goals of >€5.7 billion revenue and >€1.0 billion free cash flow still require advanced-node capex to land on schedule.

  In one sentence: ASM's moat is deep enough to make me willing to own the business for the long term, but its narrowness and competitors' capital and platformization pressure mean this moat must be continuously renewed with R&D and cannot be treated casually. It supports the "good business" judgment, but not today's €888 price and roughly 44.5x PE, which already prepay a "everything goes right" scenario.

  Jun 5, 2026
• QIf the core business is disrupted, does it have the genetic ability to reinvent itself? How does it treat mistakes and bad news?4/10

  A

  Conclusion first

  ASM has a clear "self-reinvention gene," but its version is gradual adjacent expansion plus a strong balance-sheet backstop, not a violent rebirth after a life-or-death crisis. Its posture toward mistakes and bad news is relatively honest and constructive, but much of that composure is bought by an extremely strong financial position rather than forged under adversity. This dimension is a modest positive, not a decisive strength for the Baillie "fivefold in ten years" upside case. It lowers the tail risk of "disrupted and then collapses," but it does not provide the explosive imagination of "rebuilt the company from the brink." That is fully consistent with the report's overall "good business, bad price, Watch" conclusion.

  1. If the core deposition business is disrupted, does it have the genetic ability to reinvent itself?

  Yes, and there is real historical evidence, but it should be understood as active evolution rather than rebuilding after being knocked down.

  ASM itself is the product of a successful reinvention. It started in relatively traditional thermal-processing equipment such as vertical furnaces/LPCVD. The real turning point was its 1999 acquisition of Finland's Microchemistry and Tuomo Suntola's ALD technology, which moved it from "furnace company" into a new lane and eventually made it today's single-wafer ALD leader with >55% share. The report also notes the technical gene that runs through current CEO Hichem M'Saad, who came up through thermal processing, global products, and CTO roles. This shows that ASM has indeed executed a "change the engine" level of self-reinvention, and succeeded, which many equipment companies cannot demonstrate.

  But the nature of that gene needs to be parsed honestly:

  • It is gradual adjacent capability expansion, not a cross-industry gamble. The two acquisitions in the report both sit close to the axis of "interface engineering + chemistry + deposition": the 2022 acquisition of LPE to enter SiC Epi (paid with cash + earn-out + 630,000 shares), and the 2025 acquisition of Axus to bring CMP capability into More-than-Moore and 3D integration (€81m net cash consideration + up to €30m earn-out). This pushes the circle of competence outward ring by ring, rather than entering a completely unfamiliar business. Notably, Axus explicitly does not directly confront Applied Materials / Ebara in leading-edge CMP. That shows ASM expands with discipline, choosing narrow openings it can win, with more caution than ambition.

  • Sustained heavy R&D into new nodes is its main anti-disruption battlefield. The report discloses 2025 Gross R&D of €512m, capitalized development of €205m, and Net R&D of €409m. The company ties the serviceable market of ALD/Epi to frontier evolutions such as GAA, 4F² DRAM, advanced packaging, and 1.4nm/1.0nm. External records also show continual iteration of ALD platforms, including Synergis 2018, XP8 2019, and Prominis/XP8E 2024. In other words, ASM's way to avoid disruption is to stay at the front edge of process technology and co-develop next-generation nodes with customers, not to milk mature nodes.

  But the upside imagination must be restrained: this gene is essentially that of a steady incremental innovator, not proven ability to have the core business killed by a disruptive new route, then rebuild from scratch and still win. That latter version has never been tested. If the ALD main route were replaced by some fundamental new technology, ASM would rely on adjacent product lines, strong cash, and customer relationships to cushion and shift position, not on a proven "rebuilt from the abyss" capability. The report's moat judgment, "stable with a tendency to widen, but not unassailable," is fully consistent with this: ASM can evolve, but its evolutionary step size is moderate.

  2. How does it treat mistakes and bad news?

  Relatively positive and honest. This is the more solid part of the dimension, but the key is that its honesty is supported by a strong balance sheet.

  The evidence in the report is direct and matches external disclosures:

  • It gives early warning of adverse information and does not hide it. In early 2025, the company explicitly said China revenue was expected to decline, and during the year it frankly acknowledged that China equipment sales still accounted for 30%+ but had declined year over year. In 2026 Q1, even while AI demand was strong, it still named geopolitical conflict, energy prices, GDP risk, and supply-chain pressure. This language, putting good news and bad news on the table together, sounds like a real operator rather than a pure storyteller. To avoid misreading the direction, readers need a time update: by 2026 Q1 results, the company's China message had shifted to "full-year sales expected to recover, stronger in H1". First warning honestly about downside, then updating honestly about recovery, is evidence of objective disclosure rather than selective narrative.

  • It explains bad numbers plainly instead of dressing them up. 2026 Q1 free cash flow turned negative at €48m, and management directly attributed this to working-capital outflow caused by a sudden increase in activity levels, rather than avoiding the issue. The report also warns that the company "cannot generate smooth cash flow every quarter." Management putting that in the open improves analyzability.

  • Accounting noise is transparently disclosed. The company discloses enough detail around ASMPT associate impairment/reversal effects on headline net profit and around capitalized R&D to let outsiders distinguish "accounting profit" from "operating cash flow." That transparency itself is a positive in how it treats financial complexity.

  Compared with governance red-flag companies, the difference is structural. There is no governance black box of super-voting control, related-party transactions, or aggressive dilution to conceal bad news. The capital-allocation order is "reinvest first, maintain a prudent dividend, then moderate buybacks." After 2025, the company only arranged a €150m buyback and dividend increase, rather than using aggressive buybacks to support the stock and distract from bad news. That is a mature and credible way to handle bad news.

  But the honest closing point is that this composure is underwritten by "a strong balance sheet," not by adversity-forged toughness. ASM has no debt, about €982m of cash at the end of 2026 Q1, and negative net debt/EBITDA. Because its finances are so strong, it can afford to put bad news on the table, absorb a single quarter of negative FCF, and withstand China volatility. It has never had to show under true survival pressure how it handles mistakes. That differs fundamentally from a company with no cash where one bad quarter could be fatal and reinvention is forced by survival. So its handling of bad news deserves a positive rating, but that positive reflects financial strength and decent governance more than antifragile resilience forged through a darkest hour.

  Honest characterization of Question 5

  Combining both sides, ASM is above average and steady on this dimension, but it is not the nuclear point of a Baillie-style upside story:

  • Self-reinvention gene: real (furnaces -> ALD is a textbook successful transition), but the current form is gradual adjacent expansion, with firepower concentrated in sustained R&D and disciplined M&A. The ability to survive a violent life-or-death rebirth has not been tested and should not be levered into the upside case.
  • Treatment of mistakes and bad news: honest, transparent, and free of governance black boxes, clearly better than red-flag companies; but this calm mostly rests on a debt-free balance sheet, making it "decent" rather than adversity-forged resilience.

  Together, these reduce the tail risk of "collapse if disrupted" and provide quality backing and downside guardrails. But they do not supply the narrative ammunition that "the market seriously underestimates its ability to rebuild, so it can rise fivefold over ten years." The conclusion matches "good business, bad price, Watch": Question 5 is strong enough to support "worth owning long term," but not strong enough to justify demanding fivefold returns from self-reinvention at €888 / PE 44.5x.

  Jun 5, 2026
• QDoes management, especially the founder, have a long-term view and interests deeply tied to the company? Is it willing to sacrifice current profit for five to ten years from now?4/10

  A

  Conclusion first: on the Baillie dimension of "management, especially founder," ASM is clearly split. The two items of "long-term view" and "willingness to sacrifice current profit for five to ten years from now" are solid and fit a technology-driven leader. But the Baillie framework's favorite feature, founder/owner-operator heavy ownership and deep alignment, is precisely ASM's structural weakness: this is a professional management team, with no powerful founder in control, and management's personal shareholding is symbolic rather than net-worth level. Overall this is neutral-to-positive, but definitely not a high-scoring Baillie archetype. That fits the full report's "good business, bad price, Watch" stance.

  1. Long-term view: strong. CEO Hichem M'Saad is a classic internal technologist rather than an external finance executive: he holds an MIT PhD in electronic materials science, and the company governance page says he has written 57 technical papers and holds nearly 200 issued patents. He joined in 2015 through the thermal-processing business, then served as global product head and CTO, joined the management board in 2022, became CEO in 2024, and was reappointed in 2026 through the 2030 AGM. For an equipment company built on ALD/Epi process know-how, a career grown from the process front line fits better than a pure professional manager. Capital allocation is also rational: the report states the priority as "first invest to support future growth -> maintain a strong balance sheet -> sustainable dividend -> return excess cash through buybacks", putting reinvestment ahead of buybacks and giving long-cycle targets of FY30 revenue >€5.7bn, operating margin 28-32%, and free cash flow >€1bn. Its willingness to state problems honestly also adds points: the report records management warning in early 2025 that "China revenue is expected to decline," while in 2026 Q1 it also named geopolitical conflict, energy prices, GDP, and supply-chain pressure. That is the language of a real operator, not only a storyteller.

  2. Deep alignment of interests with the company: ASM's weak point and the biggest gap from the Baillie preference. First, the report's honest point should be kept straight: in the "management and capital allocation" section, the original text admits that "public summary materials do not provide sufficiently detailed annual-report compensation detail on whether management share ownership is large enough to create very strong alignment, so I can only mark this as 'uncertain'", and the data-boundary section repeats that the judgment on "alignment strength" is cautiously positive but not full marks. I supplemented that with external evidence, and the conclusion narrows from "uncertain" to "clearly somewhat weak": third-party summaries show M'Saad directly owns only about 0.066%-0.067% of the shares (worth roughly €16-29m depending on price snapshot, versus annual compensation of about €3.8-5.7m), while all individual insiders together own only about 0.074% (about 36,000 shares). Ownership is widely dispersed among institutions (BlackRock about 8.6%, FMR about 5.0%, Norges about 4.9%, Tokyo Electron about 4.7%), with no founder family and no controlling shareholder. Recent insider direction is also net selling (M'Saad sold about 16% of his holding in 2026-04). In other words, by the Baillie ruler of "founder stakes personal wealth on the next decade," ASM is "symbolic ownership, institutionalized control, no owner-operator control." Alignment points in the right direction because executives do have shares and option incentives, but the strength is far from deep alignment, which naturally lowers its score in this framework. Honest caveat: these ownership/compensation figures are third-party summary data and may differ from line-by-line company annual report disclosures. ASM's official disclosure granularity here is indeed limited; the ASM annual report/remuneration report should be used for precise calculation.

  3. Willingness to sacrifice current profit for five to ten years from now: yes. This is the cleanest part of ASM's answer. The report shows 2025 Gross R&D of €512m, including €205m of capitalized development and €409m of current-period net R&D. R&D is a real cost center, not just "selling boxes." Management places the 2030 long-cycle targets and a strong balance sheet before shareholder returns, with buybacks kept around €150m, a level that is "actually quite modest" versus a market value of about €44bn. The report therefore characterizes it as "maintaining capital discipline" rather than "high-ROI deployment," which precisely shows the company has not used aggressive buybacks to flatter short-term per-share numbers and has instead kept cash for reinvestment. That is positive evidence of sacrificing current profit for the long term.

  Direct answer to the Baillie question: Long-term view (yes: internal technical CEO + rational capital allocation + FY30 targets + high R&D) and willingness to sacrifice current profit for the long term (yes: R&D prioritized over buybacks) both pass. But the Baillie ideal of founder/owner-operator interests deeply tied to the company is absent: ASM has a professional management team, no controlling founder, and personal ownership below one-thousandth. That is the core weakness that separates it from Baillie's ideal names, where founders are heavily invested and stake their net worth on years 3-10. Therefore this dimension is "neutral-to-positive but not a strength," consistent with the full-report view of a quality business with overdrawn valuation and a Watch rating.

  Jun 5, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth sustainable and not dependent on harming society or regulation?5/10

  A

  Conclusion first: Question 7 is medium-high for ASM, but not "institutional monopoly" strong. If ASM disappeared tomorrow, leading wafer fabs would "miss it badly": single-wafer ALD is a mission-critical process in advanced logic/DRAM production, tool-of-record switching requires years of qualification and co-development, and short-term substitution is almost impossible. That layer of indispensability is real and strong. But the distinction must be honest: ASM is a hard-to-replace leader, not an irreplaceable institutional monopoly. It has >55% share in single-wafer ALD, but only mid-20s% share in Epi, and AMAT/LAM/TEL plus Chinese vendors are all chasing in the same arena. The growth mode itself is legitimate (making chips has no social negative externality), but partly depends on the China market, which is constrained by export controls. That is a real discount on the second half of Question 7, "growth that does not harm society or regulation." Overall, strong but not full marks, consistent with "good business, bad price, Watch."

  1. How much would customers miss it tomorrow: a lot, but as a leader rather than a monopolist.

  The positive evidence is solid. The report rates switching costs as "very strong" and patent/process/IP barriers as "very strong": equipment entering advanced-node volume production requires long-cycle qualification, co-development, and accumulation of tool-of-record status. That means once leading customers lock ASM's ALD tools into a process recipe (high-k metal gate, spacer/liner, patterning layers), changing suppliers is not a procurement decision. It means years of process requalification. During a 2nm/GAA yield-ramp window, when fabs are fighting for capacity and yield hour by hour, nobody will gamble on requalification just to save some equipment cost. The report's "broad usage" among the top 20 customers and >55% single-wafer ALD share are the result of this stickiness. External research also confirms that ASM has 50-60% share in critical ALD steps at 5nm-2nm and that its SAM2 in first-generation GAA increases by about US$400m versus 3nm FinFET while gaining share in both ALD and Epi. That means it is not only locked in, but still expanding its indispensable process share at new nodes. Objectively, the "miss it" score is high: if ASM disappeared tomorrow, volume-production schedules in advanced logic and advanced memory would be materially disrupted.

  But "miss it" does not mean "no substitute exists." The report itself sets an honesty gate repeatedly: the moat is "stable with a tendency to widen, but not 'unassailable'... large customers are powerful, technology paths can change, and competitors have plenty of money." The competitors are not one company but a set: Applied Materials, Lam Research, and Tokyo Electron all have strong front-end deposition/etch capabilities, while ASM's weakness is that "scale, customer-service network, and integrated product coverage are less broad than integrated leaders." Epi is the clearest evidence: ASM has only mid-20s% global share in single-wafer silicon epitaxy and competes closely with AMAT/TEL. The same company is close to dominant in ALD but in a three-way fight in Epi. That proves its indispensability is process-level (certain ALD steps are hard to replace), not company-level institutional monopoly (the entire deposition line must use ASM). The report's first tracking indicator is "whether ALD share can still remain >55%," and a trigger for reassessment is "ALD share shifting from stable leadership to continuous losses." That itself admits this indispensability must be defended continuously rather than assumed forever.

  2. Is the growth mode sustainable and not harmful to society or regulation: the field is legitimate, but regulation/geopolitics is a real discount.

  Start with the positive: ASM's growth does not depend on harming society. It sells advanced-process deposition equipment, with downstream uses in AI, GAA logic, HBM/4F² DRAM, and advanced packaging. Making better chips does not have the addiction dynamics of consumer finance or the environmental extraction externality of exploitative models. The legitimacy of the field is clear. Growth is driven by real industrial upgrading (the report: 300mm Fab equipment investment is expected to grow +18% in 2026 and another +14% in 2027), not regulatory arbitrage or user harm.

  But Question 7's second half has one unavoidable discount for ASM: China export controls. The report states that China equipment revenue still accounted for 30%+ of total revenue in 2025, was affected by export controls, and management had already warned that China revenue would decline. This creates two issues: (1) growth partly depends on a regulated market where the regulatory direction is tightening unilaterally. The Netherlands has expanded semiconductor equipment export controls, with new rules effective on 2026-04-01 and covering certain metrology/inspection equipment, while the U.S. Congress introduced the MATCH Act in 2026-04 to further tighten chip-tool exports to China; (2) complying with regulation itself carries a revenue cost. This is the essence of Question 7's "growth not dependent on harming regulation": a company that relies on regulatory arbitrage collapses when controls tighten. ASM's posture is the opposite. It publicly stated that the new round of export controls was consistent with its previous 2025 revenue outlook and reiterated the €3.2-3.6bn revenue target. That means it chooses to lose incremental China revenue under compliance rather than maintain growth by routing around controls. Ethically, this is positive because it does not live in gray zones; from a growth-sustainability angle, it is negative because a 30%+ revenue block is in structural contraction and outside company control. Combined, the net effect is: the growth mode is legitimate, but its sustainability is materially weakened by unilateral geopolitical tightening, so it cannot receive full marks.

  3. Customer relationship structure: extremely sticky, but bargaining power is not fully on ASM's side.

  Indispensability also depends on who needs whom more. ASM is heavily dependent on single customers: the report says the top five customers account for 53%, the top ten for 72%, and two customers each contribute >10% of revenue (external FY24 figures are about top5 51% and top10 70%, same order of magnitude). This cuts both ways. It proves leading wafer fabs are deeply using ASM tools (high stickiness and high "miss it" value). It also means bargaining power is not one-way. Customers are giants such as TSMC, Samsung, and Intel, and they have their own incentives to support second sources. The report separately lists "customer concentration and bargaining risk" and sets "one or two leading customers materially reducing spending on ASM processes" as a reassessment trigger. That admits ASM is indispensable enough that customers cannot replace it quickly, but not so indispensable that it can dictate terms like an institutional monopoly. This further supports a "medium-high, not top-tier" judgment.

  Summary. On the two tests in Question 7, ASM's profile is: indispensability: very strong at the process level (ALD tool-of-record, switching costs measured in years, mission-critical production), but company-level status is "leader rather than monopoly" (Epi only mid-20s%, three integrated leaders plus Chinese peers compete); legitimacy of growth: the field has no social negative externality and the company chooses compliance rather than regulatory arbitrage (ethical positive), but 30%+ China revenue sits in structural contraction from tightening export controls (sustainability negative). If it disappeared tomorrow, customers would indeed "miss it badly" and near-term replacement would be hard. But that indispensability must be maintained by defending share at every node, and one leg of growth is tied down by geopolitics. Strong, but not full marks; consistent with the overall "good business, bad price, Watch" view, with no need to inflate it.

  Jun 5, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate with scale? Where does the money it earns go?6/10

  A

  Conclusion first: unit economics are one of ASM's relatively strongest dimensions in the Baillie ten questions. This is a genuinely profitable, high-quality business with record gross margin (51.8% in 2025), adjusted operating margin of 30.2%, operating cash flow above €1.06bn, year-end cash of €1.03bn, and no debt. It is structurally different from growth stocks that burn cash to buy growth before unit economics have worked. As scale increases, the economics generally improve through fixed-cost/R&D/supply-chain leverage plus process pricing power from high ALD share, and the money it earns is allocated in a rational order that prioritizes reinvestment. But the upside must be kept honest: the headline PE looks like 44.5x, but after treating capitalized development spending and associate-accounting noise as owner-earnings adjustments, the real multiple is about 74-85x, much more expensive; and this remains a strong-cycle business, so incremental returns fluctuate with the cycle. Unit economics themselves deserve a relatively high score, but they support the "good business" judgment and do not overturn the overall conclusion of "bad price, Watch."

  1. Unit-economic quality: genuinely high, one of the strongest dimensions

  ASM's unit economics are not a narrative; they are already visible in the financial statements. The five-year path in the report's "financial quality and owner earnings" section is solid: gross margin rose from 49.3% in 2023 to 50.5% in 2024 and then to 51.8% in 2025 (record high); adjusted operating margin rose from 28.4% in 2021 to 30.2% in 2025; operating cash flow rose from €381m to €1,061m; and year-end cash was €1,027m with no debt. I independently verified these figures: ASM's official Q4 and full-year 2025 results release confirms full-year revenue of about €3.2bn, gross margin of 51.8% (record), and adjusted operating margin of 30.2%, consistent with the report.

  The peer context makes the quality clearer. I checked AMAT and LRCX comparison data: Applied Materials and Lam Research full-year gross margins are both around 48.7%, while ASM's 51.8% is above both integrated leaders. A niche champion earning higher gross margin than far larger full-category competitors is direct evidence of process-value pricing, not brand or cost alone. On operating margin, Lam is around 35% recently and AMAT around 32%, while ASM's 30.2% is slightly lower; but given that ASM is only a fraction of their size and carries a higher R&D-to-revenue ratio to defend the ALD moat, it is still excellent.

  The most important comparison is this: this question separates ASM from "cash-burning growth stocks." Those companies often have gross margin just turning positive, negative operating cash flow, and dependence on financing. ASM, by contrast, has 51.8% gross margin, positive free cash flow, and net cash/negative leverage (net debt/EBITDA is effectively negative). To the same question, "what are the unit economics," ASM answers with a profitable, self-funding business that can support R&D and dividends. That is a structural advantage and the basic reason this question can receive a relatively high score.

  2. Scale effects: generally improving, but bounded and cycle-sensitive

  Directionally, larger scale makes unit economics better, for three reasons. First, share brings pricing power: ASM has >55% share in single-wafer ALD (report "industry structure" section), and when customers are fighting for yield and throughput at 2nm/GAA, HBM, and advanced packaging, equipment that delivers even a little more performance or yield is not very price sensitive. That is why gross margin still held at 49.8% in 2025 Q4 despite a year-over-year revenue decline. Second, fixed costs are leveraged: R&D, supply chain, and manufacturing scale are spread across revenue growth. From 2021 to 2025, revenue roughly doubled while adjusted operating margin still rose about 2 percentage points. Third, working efficiency improved: in 2025, working capital days fell from 50 days to 45 days, and year-end receivables fell from €789m to €562m, suggesting cash conversion improved rather than being generated by squeezing suppliers.

  But "improving" has two boundaries and should not be romanticized:

  • Scale is still smaller than integrated leaders. ASM's overall size is below AMAT/TEL/LAM, and its integrated product coverage and global service-network density are also thinner. The absolute thickness of scale leverage has a ceiling. This is the scale economy of a niche champion, not a platform ruler.
  • Incremental returns fluctuate with the cycle. This is a strong-cycle business, and incremental returns on invested capital are not smooth. In 2026 Q1, free cash flow turned negative at €48m, which management explained as working-capital outflow from a sudden increase in activity levels. The same business can generate negative cash in a single quarter at a cyclical turn. So "bigger scale improves economics" holds across multiple process-node cycles, but in any short window incremental returns will move with customer capex cycles. It should not be treated as a linear defensive compounding machine.

  3. Where the money goes: reinvestment first, rational order, but buyback efficiency is discounted at a high valuation

  The capital-allocation priority is consistent between the report's "management and capital allocation" section and official materials: first invest to support growth -> maintain a strong balance sheet -> pay a sustainable dividend -> return excess cash through buybacks. This is the order long-term owners want to see: R&D, capacity, and talent ahead of buybacks. Specific uses include:

  • R&D and capacity reinvestment (first priority). In 2025, Gross R&D was €512m, including €205m capitalized and net R&D of €409m; PPE capex was €218m. This is the core cash use for maintaining ALD/Epi leadership. ASM also confirmed in its FY2025 results discussion that gross R&D increased by about 10% year over year and capitalized development spending rose further.
  • Adjacent capability M&A. The 2022 acquisition of LPE (entering SiC Epi) and the 2025 acquisition of Axus Technology (bringing CMP into More-than-Moore/3D integration) are focused around adjacent capabilities in interface engineering, chemistry, and deposition. The company has not moved into unfamiliar businesses. That is reasonable, but full-cycle returns remain to be verified.
  • Dividends and buybacks (moderate returns of capital). The dividend rose from €2.75 in 2023 to €3.00 in 2024 and €3.25 in 2025; buybacks remain around a new €150m plan. I verified the official dividend and buyback page: the €3.25/share dividend was approved at the 2026-05 AGM, and the €150m buyback authorization covers 2026/2027. Relative to a market value close to €45bn, this buyback scale is very modest, more like maintenance of capital discipline than high-ROI capital deployment. At the current high valuation, buyback efficiency itself deserves a discount.

  4. Honest framing correction: headline PE 44x, real owner-earnings multiple 74-85x

  The unit economics are strong, but using them to justify the whole stock can fall into two accounting traps. The report has already flagged them, and I apply the same adjustments:

  1. Capitalized development spending should be treated as a real economic cost. In 2025, €205m was capitalized onto the balance sheet instead of fully running through the income statement. Looking only at net R&D of €409m understates the cash truly spent to defend the moat. Owner earnings must deduct this back.
  2. ASMPT associate accounting creates heavy noise. Impairments/reversals made reported net income swing sharply from 2022 to 2025. Reported net income is not the same as operating earnings power; operating cash flow and adjusted measures matter more.

  On that basis: starting with 2025 operating cash flow of €1,061m, subtract PPE capex of €218m, capitalized development of €205m, purchases of intangibles and other items of €53m, and add associate dividends of €7m, gives about €592m. If the favorable working-capital release that year is normalized back, owner earnings are about €520-600m. Against a current market value of about €44bn, the owner-earnings multiple is about 74-85x. That is not the story told by headline 44.5x PE; it is premium pricing within high-quality growth stocks. In other words, the stronger the unit economics, the more they remind you that the price has already rewarded them fully, perhaps excessively.

  Summary, consistent with "good business, bad price, Watch"

  Question 8 asks three things, and ASM's answers are all generally positive: unit economics are genuinely high quality (51.8% gross margin above AMAT/LRCX, strong cash flow, no debt, structurally different from cash-burning names); scale effects generally improve (pricing power + fixed-cost leverage + working-efficiency gains), but have scale limits and cycle-sensitive incremental returns; capital use is rational (reinvestment first, adjacent M&A, moderate returns of capital). This dimension can therefore score relatively high. It is one of the hardest pieces of evidence that ASM is a truly high-quality business. But the honest closing is that after adjusting capitalized R&D and associate noise, the real owner-earnings multiple of 74-85x is much more expensive than the headline 44x, and this is a strong-cycle business whose unit-economic compounding is not smooth. High quality, but expensive and cyclical. The "good" in unit economics is exactly why the market is willing to pay a high price, so it supports the "good business" judgment but does not overturn the "bad price" judgment. That is fully consistent with the report's "Watch" rating.

  Jun 5, 2026
• QFor it to rise fivefold in ten years, what conditions must hold simultaneously? Are those conditions realistic? What expectations are embedded in today's share price?3/10

  A

  Question 9: For it to rise fivefold in ten years, what conditions must hold simultaneously? Are those conditions realistic? What expectations are embedded in today's share price?

  Conclusion first: this is ASM's weakest link in the Baillie ten questions. A fivefold outcome over ten years requires a chain of "almost everything goes right" conditions to hold at the same time. The hardest requirement, about 17% annualized share-price return, is far above the growth implied by the company's official revenue guidance and far above the report's own neutral/optimistic return estimates. More importantly, today's roughly €888 share price has already prepaid almost all of the script of "high growth + deepening moat + manageable China + all new processes landing." It is already above the optimistic intrinsic-value upper bound of €850, leaving almost no margin of safety. The business is genuinely high quality, but the price has consumed the upside. The honest judgment: unrealistic conditions + overdrawn price, so this dimension should score low.

  1. The math of fivefold in ten years: about 17% annualized share-price return is required

  ASM's current market value is about €44bn (companiesmarketcap shows about €42-44bn, and Yahoo Finance shows a current price around €888). A fivefold increase over ten years means a market value of about €220bn, implying about 17% annualized share-price compounding sustained for ten years.

  Putting that number next to the report's own estimates shows the tension immediately: the report's expected annualized return is conservative -2%~0%, neutral 2%~5%, optimistic 7%~9%. In other words, even the report's optimistic case (7%~9%) is only about half of the 17% needed for a fivefold outcome. The fivefold case requires more than double the report's most optimistic range. This is not "slightly aggressive"; it points in the opposite direction from the report's central judgment.

  The root cause is starting valuation, not business quality. The report says it directly: "the reason neutral returns are not high is not that the company is poor; the core reason is that the starting valuation is too high." For a company priced at about 44.5x PE and about 74-85x owner earnings, adding ten years of 17% share-price growth means demanding high growth on a high base while valuation multiples also do not compress. That is inherently a low-probability event.

  2. The simultaneous condition chain, and how realistic each link is

  For 17% annualized returns to hold, the following conditions must almost all be realized simultaneously. If any link is discounted, the fivefold case fails:

  1. Revenue must keep growing at high-double-digit rates, and this condition is already not met. At its 2025-09 Investor Day, ASM's official 2030 revenue target was >€5.7bn, with 2024-2030 CAGR of "at least 12%". But starting from €3.17bn in 2025 and reaching €5.7bn in 2030 implies only about 12% CAGR over 5 years, clearly below the about 16% actually recorded from 2021-2025. In other words, the company's own official blueprint is already a growth slowdown. A fivefold market value requires sustained high-double-digit or faster revenue growth, while official guidance indicates a slowdown to about 12%. There is a structural gap between the two. Even steady delivery of this "slower but respectable" guidance is not enough to support 17% share-price returns.

  2. The strong cycle cannot "show itself" over ten years. This is the essential problem for equipment stocks. Semiconductor equipment is not smooth growth; it is long-term structural growth layered with violent short-term cycles. The report states that once "customers delay adoption, AI infrastructure investment cools, or 1.4nm/more advanced nodes slow, the company will quickly return from the valuation framework of a 'high-growth equipment company' to that of a 'cyclical equipment company.'" In fact, at the same Investor Day, ASM cut H2 2025 guidance (5%-10% lower than H1 sequentially, book-to-bill below 1.0), putting full-year growth at the lower end of the previous 10%-20% range. Over ten years, the company must pass through multiple capex cycles, yet the fivefold narrative requires cyclical downswings never to bite valuation. That conflicts with the historical nature of equipment stocks.

  3. Gross margin must remain high. It needs to stay within the company's guidance range of 47-51% for a long time (2025 was 51.8%). This is one of ASM's relative strengths and is fairly credible, but it is necessary, not sufficient. Holding gross margin does not create 17% returns out of thin air.

  4. ALD share >55% must not be eroded. The report lists share maintenance as one of the biggest uncertainties: Applied Materials, Lam Research, Tokyo Electron, and Chinese equipment makers are all investing. The moat is "stable with a tendency to widen," but the report explicitly says it would not describe the moat as "unassailable": large customers are powerful, technology paths can change, and competitors have money. The fivefold narrative requires share to stay fixed or even expand for ten years.

  5. China risk must remain manageable. China equipment revenue still accounted for 30%+ in 2025, had already declined year over year, and is affected by export controls. The report lists "China and regulation" as a risk capable of causing permanent capital loss. The fivefold case requires this 30%+ revenue block not to face cliff-like restrictions over ten years. That is an entirely exogenous variable, outside company control, and directionally negative.

  6. All new processes must land on schedule. GAA, 4F² DRAM, advanced packaging, 1.4nm/1.0nm: these are the engines supporting long-term TAM expansion. They must all land on time, and ASM must win share in all of them. If any node is delayed or ASM falls behind at any node, one cylinder of the growth engine is lost.

  7. Valuation multiples must not compress. This is the most hidden and most lethal condition. Today's PE of about 44.5x and owner-earnings multiple of about 74-85x are already at a high level. A fivefold outcome over ten years requires all six conditions above to be right and also requires the market to still give the same high multiple ten years from now. But the report warns of the opposite risk: "just a compression in the valuation multiple from 44.5x PE back toward a more normal range could consume a large part of future returns." In other words, the multiple is more likely a headwind than a tailwind.

  Multiplying these seven conditions together: condition 1 is already contradicted by official guidance, conditions 5/6/7 are exogenous or headwinds, and condition 2 conflicts with the nature of equipment stocks. The joint probability that all seven hold is low. This is not a growth-stock bet with small odds and large payoff. It is a case where everything must go right and the payoff is not especially high.

  3. What today's share price implies: the key honest point

  Today's share price around €888 has already prepaid a near-perfect execution script.

  The report's three DCF scenarios lay this out clearly: conservative about €305 (8% growth), neutral about €490 (11%), and optimistic about €810 (14%); the corresponding intrinsic-value ranges are conservative €280-400, reasonable €450-650, and optimistic €700-850. The current €888 price is already above the optimistic upper bound of €850. In other words, the market price is higher than the optimistic value calculated by assuming ASM can grow owner earnings at about 14% for the next ten years while enjoying a relatively low discount rate. The report's original wording: "You almost have to believe ASM can expand owner earnings at around 14% for the next ten years and also enjoy a lower discount rate for today's share price to be barely reasonable."

  Multiples tell the same story: PE about 44.5x (third-party data about 43-44.5x), P/S~13.3x, P/B~9.9x, EV/EBITDA~34.8x, and owner earnings about 74-85x. This is the pricing of a first-tier high-quality growth stock, not a discounted second-tier asset. The market has already fully priced in the whole optimistic package of "many years of high-double-digit growth + further deepening moat + manageable China risk + all new process routes landing on schedule".

  That means: the current price almost requires everything to go right and leaves no margin of safety. The report repeatedly emphasizes "margin of safety: insufficient," an ideal buying range of €350-500, and that above €800 is "clearly overvalued." Baillie asks "why has the market not realized this?" For ASM, the market has not only realized its quality; it has overcapitalized the upside. Good news is already the priced expectation; bad news, meaning any link missing expectations, is the unpriced risk. That is the opposite of an asset with underdrawn valuation and a real downside floor. ASM is a good business, but the price has consumed the upside, and downside from slower growth plus multiple compression is the less protected side. The report's worst-case judgment is that "a 30%-50% permanent capital loss over ten years is not unimaginable," and that "such loss mainly comes from having paid too much, not from bankruptcy risk."

  4. Assessment of this dimension

  Applying the Baillie upside lens to ASM, the honest conclusion for this question is:

  • The roughly 17% annualized return required for a fivefold outcome over ten years is far above the level implied by official revenue CAGR of about 12%, and far above the report's neutral 2-5% and optimistic 7-9% return ranges. The fivefold narrative does not hold mathematically.
  • In the seven-link condition chain, condition 1 is already contradicted by official "growth slowdown" guidance, conditions 5/6/7 are exogenous/headwind variables, and condition 2 conflicts with the strong-cycle nature of equipment stocks. The realism of simultaneous realization is low.
  • Today's €888 price is already above the optimistic intrinsic-value upper bound of €850, prepaying almost all good news and leaving almost no margin of safety. The price has overdrawn the upside and skews risk-reward downward.

  Therefore, whether judged by the feasibility of a fivefold outcome over ten years or by the expectations embedded in today's price, ASM is clearly weak on Question 9. It is a high-quality business worth long-term ownership, but not an attractive growth asset at today's price for betting on a fivefold outcome. That is fully consistent with the full report's "good business, bad price, rating Watch" conclusion: the problem was never the business, but whether you can buy it at a price that still allows error. On the ten-year-fivefold question, the answer is no.

  Jun 5, 2026
• QWhy has the market not realized all of this yet? Is it because the market does not understand it, looks down on it, or cannot look far enough? What could become the "narrative inflection point"?3/10

  A

  Conclusion first: for Baillie Q10, "why has the market not realized all of this yet," ASM's honest answer is that the market realized it long ago and has probably over-realized it. That is the core of this report's "good business, bad price, rating Watch" conclusion. Baillie asks this question to find "ignored greatness/hidden cheapness," but ASM is not a case where investors do not understand it, look down on it, or fail to look far enough. It is the opposite: the market understands it well and gives it a high premium. If any perception gap remains, it is more likely negative, meaning the market may be overestimating the sustainability of a cyclical peak, not the positive re-rating Baillie hopes for. Therefore this dimension is weak, and directionally negative, the opposite of a stock with genuine positive perception gap.

  1. Using the three lenses of "doesn't understand / looks down / can't look far," all point to "fully priced."

  • Doesn't understand? No. The market's understanding of ASM is quite thorough: it is the niche leader with >55% share in single-wafer ALD and benefits from the long runway of GAA / HBM / 4F² DRAM / advanced packaging (report "industry structure and moat" section). This narrative is a consensus among both sell-side and buy-side investors. Even the old confusion that "ASM and ASML are two different companies" is now well understood by professional capital. The market not only understands ASM; it has priced in its ALD leadership, strong balance sheet, no debt, and outcome-based services stickiness.
  • Looks down on it? No, the opposite. The current share price is about €888, TTM PE about 43-44.5x, and market value about €42-44bn (based on companiesmarketcap and Yahoo Finance around 2026-06-05). Over the past year, the Dutch semiconductor sector overall rose about +105%, far above the Dutch market's +32%, and ASM alone had rebounded about 43% from its 2026-03-30 low. During that period, a sell-side view was also upgraded to "Strong Buy". This is a chased asset, not an ignored one.
  • Cannot look far enough? Not really. The market is precisely looking far ahead and discounting the 2030 targets of >€5.7bn revenue / >€1bn FCF into the present valuation. The report's DCF shows that the current price almost requires ASM to grow owner earnings at about 14% for the next ten years while enjoying a low discount rate, with an owner-earnings multiple as high as 74-85x (report "valuation and margin of safety" section). This is not "the market has not seen the long term"; it is "the market treats the most optimistic long term as the base case."

  2. If a perception gap exists, it is likely negative: not "hidden cheapness," but possible overvaluation.

  The spirit of Baillie Q10 is to find positive perception gaps. But ASM's relative valuation cross-check shows it is not a "discounted second-best asset": peers are also expensive. The report records AMAT PE of about 47.1x, ASML about 56.6x, Tokyo Electron about 49.2x, and Lam Research about 64x, and says "peers all being expensive does not make it cheap" (report "relative valuation" section). In other words, the market has already done the work of pricing ASM as a first-tier high-quality growth stock, and positive alpha has been consumed in advance. What may not be fully priced is downside risk:

  • The sustainability of the cyclical peak may be underestimated as a risk. Current earnings and valuation sit at a favorable point of AI capex and advanced-node expansion. If customers delay adoption or AI infrastructure investment cools, ASM can quickly move from "high-growth equipment company" back to "cyclical equipment company" valuation (report risk two).
  • China and export controls are live negative variables. China equipment revenue still accounted for 30%+ in 2025 (report risk three). In 2026-04, the U.S. introduced the MATCH Act to tighten chip-equipment exports to China. Even the softened version retained restrictions on DUV / restricted fabs in China, and ASML and related sector stocks fell in response. This is a real negative variable that can hit the whole high-end equipment sector.
  • Customer concentration magnifies fragility. The top five customers account for about 53% and the top ten about 72% (report risk four). If any of a few giants changes technology roadmap or delays expansion, the impact is direct.

  3. The so-called "narrative inflection point" is more likely to be a negative catalyst than a positive re-rating for ASM.

  The Baillie-style inflection point is where the market finally discovers the company's greatness and rerates it upward. But once greatness is already priced, the likely inflection points are concentrated in valuation compression: 1. AI capex clearly cools and order momentum slows; 2. China restrictions tighten further or Chinese equipment vendors accelerate substitution at mature nodes; 3. ALD / Epi share is eroded by AMAT, Lam, Tokyo Electron, or Chinese vendors. Any one of these could move the valuation from "high-growth stock" back to "ordinary cyclical equipment stock," creating the slower growth + multiple compression double hit the report names. A 30%-50% permanent capital loss over ten years is not unimaginable (report "maximum loss risk" section). Positive inflection points, such as further share gains or upside to long-term targets, of course exist, but they are more likely to maintain the current valuation than to drive a large re-rating. The upside has already been prepaid.

  One contrast to calibrate direction: a stock that truly fits Baillie Q10 should be one where the market does not understand the business model, or dismisses it as sunset/niche, or values only the near term and not the far term, creating a positive perception gap where the company becomes cheaper as one studies it more. ASM is the opposite. The market understands it well, grants a first-tier premium, and has discounted the far term into today. The positive perception gap is weak, and the remaining perception gap is more the negative question of whether the market is overestimating the cyclical peak. Therefore, for Q10, ASM does not offer the "undervalued greatness" Baillie seeks. It is fully consistent with the whole report's "good business, bad price, Watch" judgment: worth long-term attention and possibly long-term ownership, but at today's price, the perception gap is not on your side.

  Jun 5, 2026